Prevalence of Thrombosis in COVID-Patients

Official Title

Prevalence of Thrombosis in COVID-Patients in Correlation to Humoral and Cellular Immunity

Brief Summary

Examination of the prevalence of thrombosis in COVID-patients, especially in an out-patient setting. Assessment by duplex sonography. If thrombosis is detected, we will correlate it with immunity status. Assessment of health issues and cognitive function as late complication after infection.

Status

Completed

Conditions

COVID19

Interventions

Diagnostic Test: duplex sonography

all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
Other Name: Array

Eligibility Criteria

Inclusion Criteria:

- SARS CoV 2 positive swap, at least 4 weeks after infection

Exclusion Criteria:

- under 18 years old no consent anemia

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: N/A

Countries

Germany

Locations

University Hospital Augsburg
Augsburg, Germany

Investigators

Alexander Hyhlik-Duerr, MD, Principal Investigator
University Hospital Augsburg

NCT Number

NCT04615026

MeSH Terms

Thrombosis

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

University Hospital Augsburg

Prevalence of Thrombosis in COVID-Patients

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA